Compare Organon Pharma Indonesia Tbk. (SCPI) vs Suryamas Dutamakmur Tbk. (SMDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Suryamas Dutamakmur Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Suryamas Dutamakmur Tbk. trades at Rp550 (market cap 2.62T, 50.2K 24h volume). The key difference: Suryamas Dutamakmur Tbk. is far larger — about 25.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMDM | |
|---|---|---|
Market Cap | 104.4B | 2.62T |
Volume | — | 50.2K |
Lot | — | 502 |
Turnover | — | 26.74M |
Average Price | — | 532.67 |
Value | — | 26.74M |
Indicative Equilibrium Price | — | 550 |
Indicative Equilibrium Volume | — | 2 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Suryamas Dutamakmur Tbk.
PT Suryamas Dutamakmur Tbk (the Company) was established based on notarial Deed No. 322, dated September 21, 1989 of Benny Kristianto, S.H., notary in Jakarta. PT. Suryamas Dutamakmur has a specific aim to participate in meeting the growing demand for quality residential development in the Greater Jakarta area.
Read more on SMDM →
